Il-7 variants with reduced immunogenicity

A polypeptide comprising a modified molecule human IL-7 or an active portion thereof, which has an epitope of modified to reduce a response of T anti-IL-7 cells T cells, said polypeptide comprising, and same, an Fc portion of a molecule fused immunoglobulin, via its C-terminus to the N terminus of said modified molecule IL-7, being selected such Fc-IL7 fused molecule from the group comprising: (i) the huFcy2 (h) (FN> AQ) - L - IL-7 (F39P, F57N, L128S), being Fcy2 (h) a portion of human Fc with a hinge of IgG1 and CH2 and CH3 domains of IgG2 comprising the mutations F296A and N297Q, L is a linker segment which has the sequence GGGGSGGGG, and IL-7 being (F39P, F57N, L128S) IL-7 containing the F39P, F57N mutations, and L128S; said molecule having the sequence displayed in Figure 31; (Ii) huFcy2 (h) (FN> AQ) - L - IL-7 (F39P, F57N, L77D, L128S), being Fcy2 (h) a portion of human Fc with a hinge of IgG1 and CH2 and CH3 domains of IgG2, comprising the F296A mutation and N297Q, L is a linker segment, which has the GGGGSGGGG sequence, and being IL-7 (F39P, F57N, L77D, L128S) IL-7 containing the mutations F39P, F57N, L77D and L128S; said molecule having the sequence is shown in Figure 32; (Iii) huFcy2 (h) - L - IL-7 (F39P, F57N, L77D, L128S), being Fcy2 (h) a portion of human Fc with a hinge of IgG1 and CH2 and CH3 domains of IgG2, L being a segment linker, having the sequence GGGGSGGGG, and IL-7 being (F39P, F57N, L77D, L128S) IL-7 containing the mutations F39P that, F57N, L77D and L128S; said molecule having the sequence displayed in Figure 33; and (iv) huFcy2 (h) - L - IL-7 (F39P, F57N, L128S), being Fcy2 (h) a portion of human Fc with a hinge of IgG1 and CH2 and CH3 domains of IgG2, L is a linker segment It is having the sequence GGGGSGGGG, and IL-7 being (F39P, F57N, L128S) IL-7 containing the F39P, F57N mutations, and L128S; said molecule having the sequence has been shown in Figure 34.